And the list goes on and on, like, potential merger of Kiromic and NGIO, and it’s spin out, the dividend to GNBT shareholders in the new NGIO and when public more value to our shareholders, credibility back in our old existing assets by way of Merck and the license we sold for prostate cancer, the new formulation of OL which is substantially better then the old OL, the list goes on and on and on.